171 related articles for article (PubMed ID: 21095459)
1. Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms.
Müller T
Int Rev Neurobiol; 2010; 95():49-71. PubMed ID: 21095459
[TBL] [Abstract][Full Text] [Related]
2. Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition.
Nissinen E
Int Rev Neurobiol; 2010; 95():1-5. PubMed ID: 21095456
[TBL] [Abstract][Full Text] [Related]
3. L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase.
Zhao WQ; Latinwo L; Liu XX; Lee ES; Lamango N; Charlton CG
Exp Neurol; 2001 Sep; 171(1):127-38. PubMed ID: 11520127
[TBL] [Abstract][Full Text] [Related]
4. Role of homocysteine in the treatment of Parkinson's disease.
Müller T
Expert Rev Neurother; 2008 Jun; 8(6):957-67. PubMed ID: 18505360
[TBL] [Abstract][Full Text] [Related]
5. Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa.
De Bonis ML; Tessitore A; Pellecchia MT; Longo K; Salvatore A; Russo A; Ingrosso D; Zappia V; Barone P; Galletti P; Tedeschi G
Neurosci Lett; 2010 Jan; 468(3):287-91. PubMed ID: 19909787
[TBL] [Abstract][Full Text] [Related]
6. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
Müller T; Kuhn W
Eur J Clin Pharmacol; 2006 Jun; 62(6):447-50. PubMed ID: 16758261
[TBL] [Abstract][Full Text] [Related]
7. Levodopa: past, present, and future.
Hauser RA
Eur Neurol; 2009; 62(1):1-8. PubMed ID: 19407449
[TBL] [Abstract][Full Text] [Related]
8. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
[TBL] [Abstract][Full Text] [Related]
9. L-dopa therapy for Parkinson's disease: past, present, and future.
Nagatsua T; Sawadab M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
[TBL] [Abstract][Full Text] [Related]
10. CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease.
Zhu BT
Int J Mol Med; 2004 Mar; 13(3):343-53. PubMed ID: 14767563
[TBL] [Abstract][Full Text] [Related]
11. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
Müller T; Kuhn W
Mov Disord; 2009 Jul; 24(9):1339-43. PubMed ID: 19425084
[TBL] [Abstract][Full Text] [Related]
12. Catechol-O-methyltransferase inhibitors in preclinical models as adjuncts of L-dopa treatment.
Marin C; Obeso JA
Int Rev Neurobiol; 2010; 95():191-205. PubMed ID: 21095463
[TBL] [Abstract][Full Text] [Related]
13. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease.
Müller T; Woitalla D; Hauptmann B; Fowler B; Kuhn W
Neurosci Lett; 2001 Jul; 308(1):54-6. PubMed ID: 11445284
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Müller T; Woitalla D; Muhlack S
Naunyn Schmiedebergs Arch Pharmacol; 2011 Jun; 383(6):627-33. PubMed ID: 21533995
[TBL] [Abstract][Full Text] [Related]
15. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
Müller T
Drugs; 2015 Feb; 75(2):157-74. PubMed ID: 25559423
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.
Contin M; Martinelli P; Mochi M; Riva R; Albani F; Baruzzi A
Mov Disord; 2005 Jun; 20(6):734-9. PubMed ID: 15747357
[TBL] [Abstract][Full Text] [Related]
17. O-Methylation of tea polyphenols catalyzed by human placental cytosolic catechol-O-methyltransferase.
Zhu BT; Patel UK; Cai MX; Conney AH
Drug Metab Dispos; 2000 Sep; 28(9):1024-30. PubMed ID: 10950844
[TBL] [Abstract][Full Text] [Related]
18. Catechol-O-methyltransferase and Parkinson's disease.
Reches A; Fahn S
Adv Neurol; 1984; 40():171-9. PubMed ID: 6695593
[TBL] [Abstract][Full Text] [Related]
19. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
[TBL] [Abstract][Full Text] [Related]
20. L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease.
Isobe C; Abe T; Terayama Y
J Clin Neurosci; 2010 Jun; 17(6):717-21. PubMed ID: 20356746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
